Elizabeth Anderson
Stock Analyst at Evercore ISI Group
(1.99)
# 2,767
Out of 4,814 analysts
104
Total ratings
38.89%
Success rate
-9.28%
Average return
Main Sectors:
Stocks Rated by Elizabeth Anderson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HCAT Health Catalyst | Downgrades: In-Line | $6 → $4 | $3.85 | +3.90% | 6 | Apr 9, 2025 | |
| FTRE Fortrea Holdings | Maintains: In-Line | $20 → $15 | $5.28 | +184.09% | 7 | Mar 4, 2025 | |
| MCK McKesson | Maintains: Outperform | $650 → $675 | $697.08 | -3.17% | 5 | Feb 6, 2025 | |
| ALGN Align Technology | Maintains: Outperform | $240 → $260 | $171.41 | +51.68% | 12 | Feb 6, 2025 | |
| CVS CVS Health | Maintains: Outperform | $60 → $65 | $67.28 | -3.39% | 6 | Jan 27, 2025 | |
| WBA Walgreens Boots Alliance | Maintains: In-Line | $9 → $12 | $10.80 | +11.11% | 13 | Jan 13, 2025 | |
| LH Labcorp Holdings | Upgrades: Outperform | $260 → $265 | $217.06 | +22.09% | 4 | Jan 7, 2025 | |
| XRAY DENTSPLY SIRONA | Downgrades: In-Line | $20 | $12.84 | +55.76% | 7 | Jan 7, 2025 | |
| CAH Cardinal Health | Upgrades: Outperform | $140 | $134.68 | +3.95% | 6 | Jan 7, 2025 | |
| WAY Waystar Holding | Maintains: Outperform | $32 → $36 | $36.44 | -1.21% | 4 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $8 → $9 | $6.83 | +31.77% | 2 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $270 → $265 | $143.91 | +84.14% | 5 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $34 → $45 | $53.20 | -15.41% | 7 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $7 → $4 | $4.00 | +0.13% | 4 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $23 | $15.19 | +51.42% | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: In-Line | $165 | $163.77 | +0.75% | 2 | Aug 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $20 | $23.68 | -15.54% | 3 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $68 → $26 | $11.22 | +133.96% | 3 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $35 → $15 | $5.91 | +154.02% | 3 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $11 | $3.23 | +241.09% | 2 | Jan 4, 2022 |
Health Catalyst
Apr 9, 2025
Downgrades: In-Line
Price Target: $6 → $4
Current: $3.85
Upside: +3.90%
Fortrea Holdings
Mar 4, 2025
Maintains: In-Line
Price Target: $20 → $15
Current: $5.28
Upside: +184.09%
McKesson
Feb 6, 2025
Maintains: Outperform
Price Target: $650 → $675
Current: $697.08
Upside: -3.17%
Align Technology
Feb 6, 2025
Maintains: Outperform
Price Target: $240 → $260
Current: $171.41
Upside: +51.68%
CVS Health
Jan 27, 2025
Maintains: Outperform
Price Target: $60 → $65
Current: $67.28
Upside: -3.39%
Walgreens Boots Alliance
Jan 13, 2025
Maintains: In-Line
Price Target: $9 → $12
Current: $10.80
Upside: +11.11%
Labcorp Holdings
Jan 7, 2025
Upgrades: Outperform
Price Target: $260 → $265
Current: $217.06
Upside: +22.09%
DENTSPLY SIRONA
Jan 7, 2025
Downgrades: In-Line
Price Target: $20
Current: $12.84
Upside: +55.76%
Cardinal Health
Jan 7, 2025
Upgrades: Outperform
Price Target: $140
Current: $134.68
Upside: +3.95%
Waystar Holding
Nov 7, 2024
Maintains: Outperform
Price Target: $32 → $36
Current: $36.44
Upside: -1.21%
Oct 8, 2024
Maintains: In-Line
Price Target: $8 → $9
Current: $6.83
Upside: +31.77%
Oct 8, 2024
Maintains: Outperform
Price Target: $270 → $265
Current: $143.91
Upside: +84.14%
Oct 8, 2024
Maintains: In-Line
Price Target: $34 → $45
Current: $53.20
Upside: -15.41%
Oct 8, 2024
Maintains: In-Line
Price Target: $7 → $4
Current: $4.00
Upside: +0.13%
Sep 23, 2024
Maintains: Outperform
Price Target: $18 → $23
Current: $15.19
Upside: +51.42%
Aug 28, 2024
Reinstates: In-Line
Price Target: $165
Current: $163.77
Upside: +0.75%
Jul 9, 2024
Maintains: Outperform
Price Target: $23 → $20
Current: $23.68
Upside: -15.54%
Mar 16, 2022
Maintains: In-Line
Price Target: $68 → $26
Current: $11.22
Upside: +133.96%
Mar 2, 2022
Downgrades: In-Line
Price Target: $35 → $15
Current: $5.91
Upside: +154.02%
Jan 4, 2022
Downgrades: In-Line
Price Target: $11
Current: $3.23
Upside: +241.09%